BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lonardo A. Precision medicine in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2022;37:1175-8. [PMID: 35801994 DOI: 10.1111/jgh.15850] [Reference Citation Analysis]
2 Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S, Meier F, Mann M. Defining NASH from a Multi-Omics Systems Biology Perspective. J Clin Med 2021;10:4673. [PMID: 34682795 DOI: 10.3390/jcm10204673] [Reference Citation Analysis]
3 Azkargorta M, Iloro I, Escobes I, Cabrera D, Falcon-Perez JM, Elortza F, Royo F. Human Serum Extracellular Vesicle Proteomic Profile Depends on the Enrichment Method Employed. Int J Mol Sci 2021;22:11144. [PMID: 34681804 DOI: 10.3390/ijms222011144] [Reference Citation Analysis]
4 Albhaisi S, Noureddin M. Current and Potential Therapies Targeting Inflammation in NASH. Front Endocrinol (Lausanne) 2021;12:767314. [PMID: 34925237 DOI: 10.3389/fendo.2021.767314] [Reference Citation Analysis]
5 Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12:824. [PMID: 35740949 DOI: 10.3390/biom12060824] [Reference Citation Analysis]
6 Lin SZ, Fan JG. Peripheral immune cells in NAFLD patients: A spyhole to disease progression. EBioMedicine 2021;75:103768. [PMID: 34929490 DOI: 10.1016/j.ebiom.2021.103768] [Reference Citation Analysis]
7 Liang R, Ge W, Li B, Cui W, Ma X, Pan Y, Li G. Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs. Pharm Biol 2022;60:359-73. [PMID: 35171063 DOI: 10.1080/13880209.2022.2036767] [Reference Citation Analysis]
8 Mohamed MS, Ghaly S, Azmy KH, Mohamed GA. Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00189-w] [Reference Citation Analysis]
9 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dragon-Durey MA, Chen X, Kirilovsky A, Ben Hamouda N, El Sissy C, Russick J, Charpentier E, Binois Y, Marliot F, Meylan M, Granier C, Pere H, Saldmann A, Rance B, Jannot AS, Baron S, Chebbi M, Fayol A, Josseaume N, Rives-Lange C, Tharaux PL, Cholley B, Diehl JL, Arlet JB, Azizi M, Karras A, Czernichow S, Smadja DM, Hulot JS, Cremer I, Tartour E, Mousseaux E, Pagès F. Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS One 2021;16:e0252026. [PMID: 34038475 DOI: 10.1371/journal.pone.0252026] [Reference Citation Analysis]